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Abstract
Background: The precise relationship between the lipid profile and mortality in elderly patients with type 2 diabetes
mellitus (T2DM) remains unclear. The aim of this study was to investigate the relationship between the lipid profile over
time, and mortality in elderly patients with T2DM.
Methods and Findings: In 1998, 881 primary care patients with T2DM aged 60 years and older participated in the ZODIAC
study, a prospective observational study. The cohort was divided into two age categories: 60–75 years and older than 75
years. Updated means of all lipid profile indices were calculated after a median follow-up time of 9.8 years. These values
were used as time dependent covariates in a Cox proportional hazard model. The cholesterol-HDL ratio and LDL-cholesterol
were positively related to both all-cause and cardiovascular mortality in the low age group. In contrast, except for the
triglyceride level, none of the other lipid profile indices were related to all-cause mortality in patients aged over 75 years.
The mortality risk decreased by 17% (95%CI: 5% to 27%) for each 1 mmol/L higher serum level of triglycerides. The
relationships between the various lipid profile indices and cardiovascular mortality were not significant. However, the results
were different after stratification for diabetes duration. In the subgroup of elderly patients with a diabetes duration of 8
years and longer, higher lipids were predictive of increased cardiovascular mortality. The main limitation of this study is its
observational design, which prevents us drawing conclusions about causality.
Conclusion: Although the lipid profile was not predictive in the overall group of elderly patients, higher lipids were related
to increased cardiovascular mortality in patients with diabetes of long duration. In order to make valid recommendations
concerning lipid-lowering treatment, a randomized controlled trial or a meta-analysis concerning this specific population is
mandatory.
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Introduction
Type 2 diabetes mellitus (T2DM) and dyslipidemia are
important risk factors for cardiovascular disease [1,2]. Random-
ized controlled trials have clearly demonstrated the positive effects
of lipid-lowering treatment (LLT) in T2DM, as shown in two
recent meta-analyses [3,4]. Therefore, treatment with lipid-
lowering drugs is recommended for virtually all patients with
T2DM in the various guidelines [5–7]. Although part of these
studies included patients older than 75 years, no separate analyses
were performed for this age group. The only randomized
controlled trial specifically designed for the elderly (70–82 years)
showed a reduction in cardiovascular disease risk [8]. This
reduction was largely attributable to positive effects in the
secondary prevention group, as shown in a post-hoc analysis.
The risk of cardiovascular disease was not reduced in patients with
a history of diabetes, although the number of patients with
diabetes was probably too small to permit accurate interpretation
of the treatment effect [8]. Based on the current evidence, the
question therefore remains whether there is a benefit of lowering
lipids in the elderly diabetic population. This especially holds true
for primary prevention. Also, in a cohort of patients form the
general population without verified coronary heart disease, higher
cholesterol levels were not related to an increased risk of coronary
heart disease [9]. Some other longitudinal studies, including the
Framingham study, have even observed increased all-cause
mortality rates with lower total cholesterol levels in the general
elderly population, regardless of the diabetes status [10–14]. We
aimed to explore the association between the lipid profile and the
risk of mortality in a prospectively designed cohort study of elderly
T2DM patients.
Methods
This study is part of the ZODIAC (Zwolle Outpatient Diabetes
project Integrating Available Care) study; the design and details of
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8464
which have been presented elsewhere [15]. In this study, general
practitioners are assisted by hospital-based nurses specialized in
diabetes in their care of patients with T2DM. In the first year
(1998) of the study, 1664 patients were assessed for eligibility, and
a total of 1143 patients agreed to participate in the study (see flow
diagram in figure 1). For the present study, we selected all patients
aged 60 years and older (n = 881). Baseline data consisted of a full
medical history including macrovascular complications, medica-
tion use, and tobacco consumption. Laboratory and physical
assessment data, such as lipid profile, serum creatinine levels, the
urinary albumin-to-creatinine ratio, blood pressure, weight, and
height were collected annually. Total cholesterol, HDL-cholesterol
as well as the triglyceride level were determined using standard
hospital procedures. LDL-cholesterol was calculated using the
Friedewald equation [16]. Patients were not specifically instructed
to collect a fasting lipid profile at that time. Early 2009, the life
status and cause of death were retrieved from records maintained
by the hospital and the general practitioners.
The cohort of 881 patients was divided into two age groups: 75
years and younger (low age group), and older than 75 years (high
age group). Updated means of total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides, and the cholesterol-HDL ratio
were calculated for each individual from baseline to the end of
follow-up by averaging the baseline values with the mean annual
values. This technique is similar to the one used in the United
Kingdom Prospective Diabetes Study (UKPDS) [17]. For
example, at one year the updated mean total cholesterol is the
average of the baseline and one year values and at three years it is
the average of baseline, one year, two year and three year values.
Eleven baseline variables were selected as possible confounders in
the relationship between the lipid profile indices and mortality:
gender, smoking (yes or no), body mass index (BMI), duration of
diabetes, serum creatinine level, macrovascular complications (yes
or no), albuminuria (yes or no), systolic blood pressure, use of lipid-
lowering drugs (yes or no), use of antihypertensive drugs (yes or
no), and age. Patients were considered to have macrovascular
complications when they had a history of angina pectoris,
myocardial infarction, percutaneous transluminal coronary angio-
plasty, coronary artery bypass grafting, stroke or transient
ischaemic attack.
Continuous variables are represented as mean (6 standard
deviation) for normally distributed values and as median
(interquartile range) for non-normally distributed values. Normal-
ity was evaluated using Q-Q plots. Nominal variables are
represented as the total number of patients (percentage). A Cox
proportional hazard model was used to investigate the relationship
between the updated means of the lipid profile indices, as time
dependent covariates, and mortality with and without adjustment
for the selected confounders. The model was used in both age
groups. The assumption of proportional hazards was checked by
inspecting the Schoenfeld residual plots for each predictor
variable. No substantial deviations from the plots were observed.
Low cholesterol levels seen in patients close to death can influence
the relationship between the lipid profile and mortality. Therefore,
we performed additional analyses in which we excluded the deaths
occurring in the first 4 years of follow-up. Analyses were repeated
in strata according to diabetes duration. The diabetes duration
variable was categorised into two different groups: diabetes of
short duration (below the median value) and diabetes of long
duration (the median value and higher). All analyses were
performed with SPSS version 15.0.1 (SPSS inc., Chicago, Illinois,
USA).
Ethics Statement
The ZODIAC study and the informed consent procedure was
approved by the local medical ethics committee of the Isala
Clinics, Zwolle, The Netherlands. Verbal informed consent was
obtained for all patients by the participating diabetes specialist
nurses and the consent was documented in the patients records.
According to Dutch law, written informed consent was not
necessary for this type of study in 1998. All data were analyzed
anonymously.
Results
The baseline characteristics of the study population are
presented in table 1. Diastolic blood pressure, BMI, total
cholesterol, level of triglycerides and the proportion of smoking
patients were lower in the high age group, whilst HDL-cholesterol
and serum creatinine were higher. Also, diabetes duration was
longer and complications were more prevalent. There were no
differences between groups regarding glycemic control and the
proportion of patients on oral glucose lowering agents and insulin
treatment. In the entire cohort, 95 patients (11%) received LLT at
the beginning of the study. During a median follow-up time of 9.8
years, LLT was started in 171 patients (31%) in the low age group,
and in 26 patients (8%) in the high age group. Two hundred sixty-
seven out of 326 patients (82%) died in the high age group and 198
out of 555 patients (36%) in the low age group. The proportions of
cardiovascular mortality in the high and low age groups were 43%
(114 out of 267) and 42% (83 out of 198), respectively.
Low Age Group
Figure 2 presents the hazard ratios, adjusted for the selected
confounders, for all-cause and cardiovascular mortality in both age
groups. An increase of the cholesterol-HDL ratio, as well as
increased levels of LDL-cholesterol were associated with both
increased all-cause and cardiovascular mortality in the low age
group. An increase of 1 mmol/L in the level of LDL-cholesterol
led to an increase of the hazard of cardiovascular mortality by
49% (95% confidence interval (CI) 17% to 91%). There was a
Figure 1. Flow diagram showing the selection process of the
ZODIAC and the present study.
doi:10.1371/journal.pone.0008464.g001
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Table 1. Baseline characteristics.
60–75 years .75 years p-value
n= 555 n= 326
Age (years) 69 (65–72) 80 (77–83) –
Male sex 230 (41) 118 (36) 0.124
Duration of T2DM (years) 6 (3–12) 8 (4–13) 0.001
Body mass index (kg/m2) 29.0 (64.6) 27.7 (64.4) ,0.001
Systolic blood pressure (mm Hg) 158.2 (625.1) 156.0 (624.0) 0.206
Diastolic blood pressure (mm Hg) 84.8 (611.2) 81.5 (610.8) ,0.001
Pulse pressure (mm Hg) 73.5 (620.2) 74.6 (618.9) 0.424
Total cholesterol (mmol/L) 5.7 (61.1) 5.5 (61.2) 0.009
Cholesterol-HDL ratio 5.3 (61.5) 4.9 (61.6) 0.001
LDL-cholesterol (mmol/L) 3.4 (61.0) 3.3 (61.0) 0.191
HDL-cholesterol (mmol/L) 1.1 (60.3) 1.2 (60.4) 0.016
Triglycerides (mmol/L) 2.6 (61.5) 2.2 (61.4) ,0.001
HbA1c (%) 7.5 (61.4) 7.4 (61.2) 0.205
Smoking 85 (15) 31 (10) 0.014
Albuminuria present 245 (44) 181 (56) 0.002
Macrovascular complications present 208 (37) 149 (46) 0.016
Receiving antihypertensive treatment 277 (50) 197 (60) 0.002
Receiving lipid-lowering treatment 80 (14) 15 (5) ,0.001
Receiving oral glucose lowering agents 406 (73) 234 (72) 0.659
Receiving insulin treatment 94 (17) 66 (20) 0.219
Serum creatinine (umol/L) 92 (82–104) 98 (86–117) ,0.001
Data are means (6 SD), medians (interquartile range) or n (%). Chi-squared tests were used for categorical variables and independent t-tests or Mann-Whitney U tests,
where appropriate, for continuous variables.
doi:10.1371/journal.pone.0008464.t001
Figure 2. Combined forest plot: lipid profile and mortality. Hazard ratios and the 95% confidence intervals of the various lipid profile indices
for all-cause and cardiovascular mortality in both age groups, adjusted for the selected confounders.
doi:10.1371/journal.pone.0008464.g002
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non-significant positive relationship between total cholesterol and
all-cause as well as cardiovascular mortality. The relationships for
both HDL-cholesterol and triglycerides with mortality were also
non-significant.
High Age Group
Except for the triglyceride level, none of the other lipid profile
indices were related to all-cause mortality in the high age group.
The mortality risk decreased by 17% (95%CI 5% to 27%) for each
1 mmol/L higher level of triglycerides. All associations between
the lipid profile indices and cardiovascular mortality were non-
significant.
Exclusion of Early Mortality
After exclusion of the deaths in the first years of follow-up the
relationship between LDL-cholesterol and mortality became more
pronounced in the low age group, but did not relevantly change in
the group of the elderly diabetic patients (figure 3). The same effect
was also seen regarding total cholesterol (data not shown). All
other associations, including the one between triglycerides and all-
cause mortality, did not relevantly change after exclusion of early
mortality.
Diabetes Duration
When the analyses were repeated in strata according to diabetes
duration, the results differed from the overall results (figure 4). For
patients in the low age group with diabetes of long duration ($6
years), the cholesterol-HDL ratio and LDL-cholesterol were
positively associated with both all-cause and cardiovascular
mortality. HDL-cholesterol was inversely related to cardiovascular
mortality in this group. Only the triglyceride level was related to
all-cause mortality for patients in the low age group with diabetes
of short duration: this relationship was inverse.
The lipid profile was not predictive of all-cause mortality in the
high age group, regardless of diabetes duration. An increase of the
cholesterol-HDL ratio, as well as increased levels of total and
LDL-cholesterol were associated with increased cardiovascular
mortality in elderly patients with diabetes of long duration ($8
years).
Discussion
After a median follow-up time of almost 10 years, the overall
results showed that higher lipid levels were unrelated to increased
all-cause and cardiovascular mortality in patients with T2DM
aged over 75 years. However, the results were different when
stratified for diabetes duration. In elderly patients with a diabetes
duration of 8 years or longer, higher lipids were related to
increased cardiovascular mortality. The overall results showed an
inverse relationship between the triglyceride level and all-cause
mortality in the high age group. An increase of 1 mmol/L led to a
decrease in mortality risk of 17%. In younger patients we found
relations as one would expect, e.g. a higher LDL-cholesterol is
related to increased mortality.
With increasing age, age itself becomes more important in the
prediction of mortality. As a consequence, the predictive value of
other risk factors like lipid profile abnormalities becomes smaller.
Interestingly, in the high age group we only found positive
relationships in patients with diabetes of long duration. These
results correspond with a previous study that showed that patients
with middle age- and elderly onset diabetes appear to represent
distinct groups with differing burdens of disease [18]. One could
hypothesize that patients with diabetes of long duration may
represent a selected group with a worse cardiovascular risk profile
compared to patients with diabetes of short duration. So, the
predictive value of the lipid profile may be higher in patients with
diabetes of long duration, because the total cardiovascular
mortality risk in this group may be higher. However, this
hypothesis could not be confirmed in our cohort: the proportions
of cardiovascular mortality for the elderly patients with diabetes of
Figure 3. Exclusion of early mortality. Hazard ratios and their 95% confidence intervals (adjusted for confounders) of LDL-cholesterol for all-
cause and cardiovascular mortality after exclusion of the deaths in the first follow-up years. Hazard ratios of several analyses in both age groups are
presented: an analysis including all follow-up years, an analysis in which the first year of follow-up was excluded, an analysis in which the first two
years of follow-up was excluded and so forth.
doi:10.1371/journal.pone.0008464.g003
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short and long duration were 47% and 54%, respectively
(p = 0.907).
Low total cholesterol has been described before as a marker of
increased mortality in the general elderly population [10–14]. We
found an inverse relationship between the triglyceride level and
all-cause mortality in both the total group of patients older than 75
years, and in a subgroup of younger patients with diabetes of short
duration. Various explanations have been proposed for the
absence of a positive relationship and sometimes an inverse
relationship, between lipids and mortality. Lower cholesterol levels
may represent occult disease or may be a signal of declining health
[13]. It is also possible that subjects surviving long enough with a
higher cholesterol are less susceptible to the adverse consequences
of dyslipidemia; those individuals susceptible to the effects of high
cholesterol will probably die before reaching the age of 75 years.
Those individuals who survive, represent a selected group with
lower cholesterol levels and with a genetic makeup or other factors
protecting them from the effects of higher cholesterol levels [12].
To adjust for the possible confounding effects of co-morbidity and
frailty, we performed additional analyses in which we excluded
deaths occurring in the first years of follow-up. The relationship
between the triglyceride level and all-cause mortality remained
inverse. All other lipid profile indices remained non-predictive of
mortality in the high age group.
In very old people from the general population with no history
of cardiovascular disease, classic risk factors included in the
Framingham risk score did not predict cardiovascular mortality
[19]. This study and the previously mentioned studies, that showed
an inverse relationship between cholesterol and mortality, question
the ability of lipid profile abnormalities to identify elderly patients
at high risk of (cardiovascular) mortality [10–14,19]. It seems
therefore that classic risk factors may have different consequences
when assessed in elderly patients. However, it is important to
emphasize that older adults exhibit widely heterogeneous health
status, ranging from healthy to frail [20,21]. In a guideline for
improving diabetes care in older adults, it has been suggested to
treat lipid profile abnormalities only after overall health status has
been considered [20]. Furthermore, it was stated that only 2 to 3
years are required to see benefits from LLT [20]. Physicians caring
for elderly diabetic patients should take co-morbidity and the
estimated life expectancy into account when setting treatment
goals for the individual patient. In our opinion, it is plausible that
there are specific groups in which lipids are predictive of mortality
and LLT is beneficial; perhaps in elderly patients with diabetes of
long duration.
The proportion of patients receiving LLT at the start of the
ZODIAC-study was small in both age categories. As a
consequence, it was not possible to perform separate analyses for
the effects of LLT on mortality. One has to remember that this
study started in 1998, and the treatment goals for the lipid profile
in patients with T2DM are more stringent nowadays. Whether
LLT is beneficial in elderly patients with T2DM remains
unanswered in this study. Several trials have investigated the
effects of statins in patients with T2DM. One large randomized
controlled trial, including 5963 diabetic patients, showed beneficial
effect of LLT on major vascular events in elderly T2DM patients
($65 years) [22]. Furthermore, a meta-analysis investigating the
effects of LLT in diabetic patients also performed a separate
analysis for patients aged 65 years and older [4]. The relative risk
for major vascular events was 0.81 (95%CI 0.71 to 0.92) in favor of
LLT. Again, only a few studies had included patients aged over 75
years.
The main limitation of this study is its observational design,
which prevents us drawing conclusions about causality. Another
limitation is that we are not informed about the proportion of non-
fasting lipid profiles during the yearly assessments in our study
population. However, a fasting blood sample is not necessary for a
reliable measurement of total cholesterol and HDL-cholesterol.
Our study also has notable strengths. Firstly, we used the
various lipid profile indices as time dependent covariates and by
means of this analysis we corrected for changes over time.
Secondly, with a median follow-up of almost 10 years, we were
Figure 4. Combined forest plot: short versus long diabetes duration. Hazard ratios and the 95% confidence intervals of the various lipid
profile indices stratified for diabetes duration (, median value versus median value and higher), adjusted for the selected confounders.
doi:10.1371/journal.pone.0008464.g004
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able to observe a substantial number of deaths to base our
conclusions on.
To our knowledge this is the first prospective observational
study which specifically investigated the relationship between lipids
and mortality in a cohort of T2DM patients older than 75 years.
Although the lipid profile was not predictive in the overall group of
elderly patients, higher lipids were related to increased cardiovas-
cular mortality in patients with diabetes of long duration. So, it
may be necessary to formulate different treatment goals for
different patients groups. In order to identify these specific groups
and to make valid recommendations concerning LLT, a
randomized controlled trial or a meta-analysis concerning this
specific population is mandatory.
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